Amgen’s Repatha Cholesterol Drug Cuts Risk of Cardiovascular Events in Clinical Trial
HTML-код
- Опубликовано: 29 авг 2024
- On www.xtalks.com - Initial results from Amgen’s FOURIER clinical trial show that Repatha reduces the risk of cardiovascular events in patients with heart disease.
To read more: xtalks.com/Repa...
For more news stories, visit: xtalks.com/News...
Receive weekly news updates right in your inbox: xtalks.com/subs...
Listen live and interact with featured speakers on our upcoming Life Science webinars: xtalks.com/upco...
Thank you for the information